Wednesday, January 21, 2015

ADC emerge as leading cancer treatment option

Antibody Drug Conjugates (ADCs) are an ideal way to target cancer cells while missing the cancer cells.  Two ADCs have jumped to the top of the treamtent list -brentuximab vedotin which treats lymphomia and ado-trastuzumab emtansine which treats breast cancer.

As their success grows, and more therapies using this technology are being developed, finding safe manufacturing methods for ADCs has posed to be the next big challenge. According to BioProcess International, there are four key factors of an ADC that must be in tact to produce a working ADC: the antigen, the targeting antibody, the linker, and the payload. In order to create more drugs at a larger scale, researchers are focusing development methods that reduce heterogeneity and ways to create site-specific conjugations.  Not only that, but finding these two things are some of the next key challenges for scientists:
  • -How to increase clinical impact for tumors that display heterogeneous expression of a target antigen
  • -How to improve outcomes for those ADCs that show promising early efficacy before tumors develop resistance.

What do you see as the next big breakthrough in antibody drug conjugate therapy?

This year at BDP Week, we'll have an afternoon dedicated to New Modalities and Next Generation ADCs – Challenges in Development and Production with presentations from companies including MedImmune, Sutro Biopharma Inc. and CytomX Therapeutics, Inc.  For more information on this session and the rest of the program, download the agenda.  As a reader of this blog, when you register to join us and mention code XB15155BLOGJP to save 20% off the standard rate.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment